Core Viewpoint - Shanghai Salen Biotechnology Co., Ltd. has initiated the online sales of its rabies immune serum in certain provinces, marking a significant step in expanding its product offerings and potential revenue streams [1][2]. Group 1: Product Information - The rabies immune serum is designed to neutralize the rabies virus and is intended for individuals who have been severely bitten or scratched by suspected rabid animals [1]. - The product is an injectable formulation, with each vial containing 2.0ml and a minimum of 400 IU of rabies antibodies [1]. Group 2: Market Context - The rabies prevention drugs are categorized into two main types: active immunization agents (rabies vaccines) and passive immunization agents (rabies immune serum, rabies human immunoglobulin, and rabies monoclonal antibodies) [2]. - Currently, the market predominantly utilizes rabies human immunoglobulin as a passive immunization agent [2]. Group 3: Application and Impact - The rabies immune serum is utilized in emergency departments or animal injury clinics that are qualified to handle dog bite cases [2]. - As the only company with a marketed rabies immune serum, the launch is expected to enhance the company's product pipeline and provide more treatment options for doctors and patients, potentially leading to new revenue growth [2].

证券代码：688163 证券简称：赛伦生物 公告编号：2025-021 上海赛伦生物技术股份有限公司 关于使用自有资金支付募投项目人员费用 并以募集资金等额置换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海赛伦生物技术股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日 召开第四届董事会第八次会议，审议通过了《关于使用自有资金支付募投项目人 员费用并以募集资金等额置换的议案》，同意公司在募投项目实施期间，根据实 际需要，先行使用自有资金支付募投项目人员费用，后续定期从募集资金专户划 转等额资金至公司自有资金账户进行置换，该部分等额置换资金视同募投项目使 用资金，上述事项无需提交公司股东会审议。保荐机构方正证券承销保荐有限责 任公司对本事项出具了明确的核查意见。现将具体情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可【2022】204 号）的批准，公司获准向 社会公开发行人民币普通股 2,706 万股，每 ...

Core Viewpoint - Shanghai Sailun Biotechnology Co., Ltd. has reported on the management and usage of raised funds for the first half of 2025, detailing the total amount raised, expenditures, and remaining balances in compliance with regulatory requirements [1][2]. Fundraising Overview - The company raised a total of RMB 89,379.18 million by issuing 27.06 million shares at a price of RMB 33.03 per share, with all funds received by March 4, 2022 [1]. - As of June 30, 2025, the cumulative usage of raised funds amounted to RMB 283,688,338.64, leaving a balance of RMB 559,847,593.49 [1][2]. Fund Management - The company has established a fundraising management system to ensure the effective use of raised funds, adhering to relevant laws and regulations [1]. - A tripartite supervision agreement has been signed with various banks to ensure the proper management of the funds [1][2]. Fund Usage Details - The company has utilized raised funds for specific projects, including: - Special drug and innovative technology research: RMB 6,080,130.83 - Emergency drug network service project: RMB 5,651,013.32 - Factory expansion project: RMB 28,113,571.80 - The total balance in the fundraising account as of June 30, 2025, was RMB 559,847,593.49 after accounting for expenditures and income from financial products [1][2]. Idle Fund Management - The company approved the use of up to RMB 550 million of temporarily idle funds for cash management, with a balance of RMB 490 million invested in structured deposits as of June 30, 2025 [2][5]. - The company has generated income from cash management activities while ensuring that project construction and fund safety are not compromised [2][5]. Surplus Fund Usage - Surplus funds from the completed emergency drug network service project, amounting to RMB 7,851,987.11, will be permanently used to supplement the company's working capital [2][5]. - The company has not encountered any changes in the use of raised funds or any violations in fund management [2][5].

Core Viewpoint - The company has conducted a semi-annual evaluation of its "Quality Improvement and Efficiency Enhancement" action plan for 2025, focusing on maintaining shareholder interests and promoting high-quality development [1][9]. Group 1: Business Performance - The company achieved a net profit attributable to shareholders of 32.98 million yuan, a year-on-year increase of 2.07%, and a net profit of 28.53 million yuan after deducting non-recurring gains and losses, reflecting a growth of 25.08% compared to the same period last year [2]. - The company has strengthened its focus on medical education and market promotion, enhancing public awareness and service levels for snakebite treatment through initiatives like the "Sailun 100 Snakebite Prevention" WeChat mini-program [2]. Group 2: Research and Development - The company is advancing its major research projects, including the clinical phase II study of the anti-viper venom serum and the submission of the Pre-IND for the anti-bee venom serum [3]. - New projects have been initiated for broad-spectrum anti-snake venom antibody drugs and recombinant snake venom coagulase, currently in the laboratory research phase [3]. Group 3: Operational Management - The company is optimizing its operational management by enhancing cash flow control, improving production efficiency, and managing costs effectively [4]. - Measures include optimizing production plans, strengthening equipment maintenance, and controlling sales and management expenses to improve unit cost output rates [4]. Group 4: Corporate Governance - The company is committed to improving its governance and internal control systems, ensuring compliance with regulations and enhancing decision-making processes [5]. - The board of directors has held multiple meetings to ensure effective governance and oversight [5]. Group 5: Investor Relations - The company is focused on enhancing its investor return mechanisms, planning to distribute a cash dividend of 1.20 yuan per 10 shares, totaling 12.99 million yuan [6]. - The company emphasizes transparent profit distribution policies and aims to provide stable cash dividends to shareholders [6]. Group 6: Project Management - The company is actively managing its fundraising projects, ensuring compliance with fundraising management regulations and advancing project implementation [7]. - The expansion project for the factory has progressed according to schedule, with key construction and equipment procurement activities underway [7]. Group 7: Communication and Disclosure - The company prioritizes effective communication with investors, ensuring timely and clear information disclosure to enhance understanding of its operations and investment value [8]. - Various channels, including performance briefings and investor meetings, are utilized to strengthen relationships with investors [8].

Core Viewpoint - Shanghai Serum Bio-Technology Co., Ltd. reported a steady growth in revenue and net profit for the first half of 2025, with a focus on the development and production of antiserum and antitoxin products, particularly in the field of biological safety and toxin treatment [1][2]. Company Overview and Financial Indicators - The company achieved an operating income of 100.82 million yuan, a 2.82% increase compared to the same period last year [2][3]. - The total profit reached 37.77 million yuan, reflecting a 1.92% increase year-on-year [2][3]. - The net profit attributable to shareholders was 32.98 million yuan, up 2.07% from the previous year [2][3]. - The net assets attributable to shareholders were 1.11 billion yuan, a 1.03% increase from the end of the previous year [2][3]. Industry and Main Business Situation - The company operates in the pharmaceutical manufacturing industry, specifically in the biopharmaceutical sector focusing on antiserum and antitoxin production [4][5]. - The company is a leader in the antiserum and antitoxin field, producing unique products such as antivenom for snake bites and tetanus immunoglobulin, which have reached advanced production levels [4][5]. - The antivenom products are the only effective treatments for snake bites in China, with no direct substitutes available [4][5]. Research and Development - The company is actively engaged in the research and development of new antivenom products, including specific antivenoms for viper bites and bee venom, which are currently in various stages of clinical trials [10][12]. - The company has established a strong technical foundation in the production of antiserum and antitoxin, with proprietary technologies in antigen purification, immune response enhancement, and virus inactivation [15][18]. - New projects include the development of broad-spectrum antivenom and recombinant snake venom coagulants, aimed at improving treatment options for snake bites and enhancing surgical hemostasis [10][12][13]. Market Expansion - The company has strengthened its market presence through educational initiatives and improved public awareness regarding snake bite treatment, enhancing the accessibility of its products [13][14]. - The company is also working on improving the procurement and distribution of its rabies antiserum, which has shown significant results in clinical applications [14].

上海赛伦生物技术股份有限公司2025 年半年度报告摘要 公司代码：688163 公司简称：赛伦生物 上海赛伦生物技术股份有限公司 上海赛伦生物技术股份有限公司2025 年半年度报告摘要 第一节 重要提示 规划，投资者应当到上海证券交易所网站（www.sse.com.cn）网站仔细阅读半年度报告全文。 公司已在本报告中描述可能存在的风险，敬请查阅"第三节 管理层讨论与分析"之"四、风险因素" 部分的内容，请投资者注意投资风险。 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 经董事会决议，公司 2025 年半年度利润分配方案为：向全体股东每 10 股派发现金红利 1.20 元（含税）。截至审议本次利润分配方案的董事会召开日，公司总股本 108,220,000 股，以此计算 合计拟派发现金红利人民币 12,986,400.00 元（含税），占公司 2025 年 1-6 月合并报表归属上市 公司股东净利润的比例为 39.38%。本次利润分配不送红股，不以资本公积金转增股本。 根据公司 2024 年年度股东大会对 2025 年中期现金分红事项的授权，本次 2025 年半年度利润 分配方案已经第四届董事会 ...

Core Viewpoint - The company has initiated the online sales of its rabies immune globulin product in certain provinces, marking a significant step in its commercialization efforts [1] Group 1: Product Development and Sales - The rabies immune globulin product has been listed on drug procurement information platforms in some provinces, indicating the start of its sales [1] - Previously, the product faced challenges in sales due to distribution channel issues and a high incidence of allergic reactions [1] - Continuous improvements in the production process have been made, with production scheduled for the second half of 2024 and ongoing efforts to expand its listing on procurement platforms into 2025 [1]

（文章来源：证券日报） 证券日报网讯 8月25日晚间，赛伦生物发布公告称，2025年半年度公司实现营业收入100，819，362.78 元，同比增长2.82%；归属于上市公司股东的净利润为32，976，733.37元，同比增长2.07%。 ...

Group 1 - The core point of the article is that Sairun Biotech has announced the launch of its rabies serum product, which is now listed on drug procurement information platforms in several provinces, indicating the start of sales [2] Group 2 - The announcement was made on the evening of August 25, highlighting the company's progress in bringing its product to market [2] - The rabies serum product is significant for public health, as it addresses a critical need for rabies treatment [2] - The listing on procurement platforms suggests that the company is actively engaging with healthcare systems to distribute its product [2]

赛伦生物(688163.SH)披露2025年半年度报告，报告期公司实现营收1.01亿元，同比增长2.82%;归母净利 润3298万元，同比增长2.07%;扣非净利润2853万元，同比增长25.08%;基本每股收益0.30元。公司拟向全 体股东每10股派发现金红利1.20元(含税)。 ...